Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | TOP1 | P11387 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7033550 | 0.74 | CYP3A4 (0.54) | CYP3A4NAMPTXDHMAPTRAB9A | |
| SCHEMBL15022727 | 0.74 | CYP3A4 (0.54) | CYP3A4NAMPTXDHMAPTNPBWR1 | |
| SCHEMBL7090036 | 0.74 | DPP4 (0.51) | CYP3A4MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8889428 | 0.74 | METAP2 (0.50) | CYP3A4TOP1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL27476007 | 0.74 | MEN1 (0.60) | CYP3A4NAMPTXDHNPBWR1MEN1 | |
| SCHEMBL23579937 | 0.74 | METAP1 (0.48) | CYP3A4NAMPTXDHMAPTSMN1; SMN2 | |
| SCHEMBL29385458 | 0.74 | METAP1 (0.48) | CYP3A4NAMPTXDHMAPTSMN1; SMN2 | |
| SCHEMBL2919852 | 0.74 | CYP3A4 (0.50) | CYP3A4NAMPTXDHMAPTMEN1 | |
| SCHEMBL2919937 | 0.74 | CYP3A4 (0.50) | CYP3A4NAMPTXDHMAPTSMN1; SMN2 | |
| SCHEMBL23579646 | 0.71 | DPP4 (0.44) | CYP3A4NAMPTMAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339150-B2 | Benzimidazole compounds as HDAC6 inhibitors | ONKURE, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220041584-A1 | BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORS | ONKURE, INC. (US) | 2022-02-10 | — | — | US | disclosed |
| WO-2021133957-A1 | BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORS | ONKURE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-2041118-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041584-A1 | BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC11 | CYP3A4 2771/4885NAMPT 1664/4885XDH 530/4885 |
| US-11339150-B2 | Benzimidazole compounds as HDAC6 inhibitors | HDAC6, HDAC1, HDAC11 | CYP3A4 2771/4885NAMPT 1664/4885XDH 530/4885 |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | MAPT, IAPP, MYLK2 | CYP3A4 1141/4885NAMPT 1151/4885XDH 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.